{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:16:12Z","timestamp":1794694572882,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z231100007223011"],"award-info":[{"award-number":["Z231100007223011"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32222045 and 32171384"],"award-info":[{"award-number":["32222045 and 32171384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471450 and 82402462"],"award-info":[{"award-number":["32471450 and 82402462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Mater."],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41563-026-02661-z","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:35:49Z","timestamp":1782912949000},"page":"1658-1669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intranasal DNA nanocarrier vaccines with surface-patterned antigens enhance efficacy against respiratory syncytial virus"],"prefix":"10.1038","volume":"25","author":[{"given":"Xiaoyu","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabeini","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingfei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinze","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-9793","authenticated-orcid":false,"given":"Guangjun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6646-0095","authenticated-orcid":false,"given":"Keman","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4504-5670","authenticated-orcid":false,"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2661_CR1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946\u2013958 (2017).","journal-title":"Lancet"},{"key":"2661_CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"2661_CR3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","volume":"89","author":"AZ Kapikian","year":"1969","unstructured":"Kapikian, A. Z., Mitchell, R. H., Chanock, R. M., Shvedoff, R. A. & Stewart, C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405\u2013421 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"2661_CR4","doi-asserted-by":"crossref","first-page":"13961","DOI":"10.1073\/pnas.94.25.13961","volume":"94","author":"RA Karron","year":"1997","unstructured":"Karron, R. A. et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA 94, 13961\u201313966 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2661_CR5","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30292-5","volume":"18","author":"NI Mazur","year":"2018","unstructured":"Mazur, N. I. et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect. Dis. 18, e295\u2013e311 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"2661_CR6","doi-asserted-by":"crossref","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","volume":"1","author":"MS Gilman","year":"2016","unstructured":"Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).","journal-title":"Sci. Immunol."},{"key":"2661_CR7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"2661_CR8","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","volume":"7","author":"JO Ngwuta","year":"2015","unstructured":"Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2661_CR9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2021.03.004","volume":"54","author":"M Mukhamedova","year":"2021","unstructured":"Mukhamedova, M. et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity 54, 769\u2013780 (2021).","journal-title":"Immunity"},{"key":"2661_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nsmb.3267","volume":"23","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23, 811\u2013820 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2661_CR11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"2661_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","volume":"365","author":"MC Crank","year":"2019","unstructured":"Crank, M. C. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505\u2013509 (2019).","journal-title":"Science"},{"key":"2661_CR13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2661_CR14","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2661_CR15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi, A. et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 388, 595\u2013608 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2661_CR16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh, E. E. et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N. Engl. J. Med. 388, 1465\u20131477 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2661_CR17","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.vaccine.2023.05.011","volume":"41","author":"E Kehagia","year":"2023","unstructured":"Kehagia, E., Papakyriakopoulou, P. & Valsami, G. Advances in intranasal vaccine delivery: a promising non-invasive route of immunization. Vaccine 41, 3589\u20133603 (2023).","journal-title":"Vaccine"},{"key":"2661_CR18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jconrel.2022.09.044","volume":"351","author":"Z Teng","year":"2022","unstructured":"Teng, Z. et al. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity. J. Control. Release 351, 456\u2013475 (2022).","journal-title":"J. Control. Release"},{"key":"2661_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","volume":"10","author":"S Al-Halifa","year":"2019","unstructured":"Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S. & Archambault, D. Nanoparticle-based vaccines against respiratory viruses. Front. Immunol. 10, 22 (2019).","journal-title":"Front. Immunol."},{"key":"2661_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"2661_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","volume":"15","author":"R Veneziano","year":"2020","unstructured":"Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716\u2013723 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2661_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41590-023-01597-9","volume":"24","author":"JF Brooks","year":"2023","unstructured":"Brooks, J. F. et al. Molecular basis for potent B cell responses to antigen displayed on particles of viral size. Nat. Immunol. 24, 1762\u20131777 (2023).","journal-title":"Nat. Immunol."},{"key":"2661_CR23","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","volume":"56","author":"S Ols","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425\u20132441 (2023).","journal-title":"Immunity"},{"key":"2661_CR24","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1955812","volume":"13","author":"W Harshbarger","year":"2021","unstructured":"Harshbarger, W. et al. Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein. mAbs 13, 1955812 (2021).","journal-title":"mAbs"},{"key":"2661_CR25","doi-asserted-by":"crossref","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","volume":"11","author":"MS Gilman","year":"2015","unstructured":"Gilman, M. S. et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog. 11, e1005035 (2015).","journal-title":"PLoS Pathog."},{"key":"2661_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41551-022-00902-5","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791\u2013805 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2661_CR27","volume":"11","author":"Z Huang","year":"2024","unstructured":"Huang, Z. et al. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses. Natl Sci. Rev. 11, nwad310 (2024).","journal-title":"Natl Sci. Rev."},{"key":"2661_CR28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431 (2019).","journal-title":"Cell"},{"key":"2661_CR29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","volume":"184","author":"PJM Brouwer","year":"2021","unstructured":"Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188\u20131200 (2021).","journal-title":"Cell"},{"key":"2661_CR30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","volume":"53","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315\u20131330 (2020).","journal-title":"Immunity"},{"key":"2661_CR31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/anie.201105846","volume":"51","author":"B Sacc\u00e0","year":"2012","unstructured":"Sacc\u00e0, B. & Niemeyer, C. M. DNA origami: the art of folding DNA. Angew. Chem. 51, 58\u201366 (2012).","journal-title":"Angew. Chem."},{"key":"2661_CR32","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1039\/D0CS00255K","volume":"50","author":"G Kong","year":"2021","unstructured":"Kong, G. et al. DNA origami-based protein networks: from basic construction to emerging applications. Chem. Soc. Rev. 50, 1846\u20131873 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"2661_CR33","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1021\/acs.chemrev.6b00825","volume":"117","author":"F Hong","year":"2017","unstructured":"Hong, F., Zhang, F., Liu, Y. & Yan, H. DNA origami: scaffolds for creating higher order structures. Chem. Rev. 117, 12584\u201312640 (2017).","journal-title":"Chem. Rev."},{"key":"2661_CR34","first-page":"e17","volume":"1","author":"X Wang","year":"2022","unstructured":"Wang, X. & Zhao, X. Controllable protein network based on DNA-origami and biomedical applications. MedComm-Biomater Appl. 1, e17 (2022).","journal-title":"MedComm-Biomater Appl."},{"key":"2661_CR35","doi-asserted-by":"crossref","first-page":"13471","DOI":"10.1039\/D2CC05335G","volume":"58","author":"S Kr\u00f6ll","year":"2022","unstructured":"Kr\u00f6ll, S., Schneider, L., Wadhwani, P., Rabe, K. S. & Niemeyer, C. M. Orthogonal protein decoration of DNA nanostructures based on SpyCatcher-SpyTag interaction. Chem. Commun. 58, 13471\u201313474 (2022).","journal-title":"Chem. Commun."},{"key":"2661_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44869-0","volume":"15","author":"EC Wamhoff","year":"2024","unstructured":"Wamhoff, E. C. et al. Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds. Nat. Commun. 15, 795 (2024).","journal-title":"Nat. Commun."},{"key":"2661_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53937-4","volume":"15","author":"Q Feng","year":"2024","unstructured":"Feng, Q. et al. Rationally designed multimeric nanovaccines using icosahedral DNA origami for display of SARS-CoV-2 receptor binding domain. Nat. Commun. 15, 9581 (2024).","journal-title":"Nat. Commun."},{"key":"2661_CR38","volume":"19","author":"N Ma","year":"2023","unstructured":"Ma, N. et al. Nanoscale organization of TRAIL trimers using DNA origami to promote clustering of death receptor and cancer cell apoptosis. Small 19, e2206160 (2023).","journal-title":"Small"},{"key":"2661_CR39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsnano.2c08880","volume":"17","author":"N Ma","year":"2023","unstructured":"Ma, N. et al. Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis. ACS Nano 17, 437\u2013452 (2023).","journal-title":"ACS Nano"},{"key":"2661_CR40","doi-asserted-by":"crossref","first-page":"26523","DOI":"10.1073\/pnas.1909653116","volume":"116","author":"AH Keeble","year":"2019","unstructured":"Keeble, A. H. et al. Approaching infinite affinity through engineering of peptide\u2013protein interaction. Proc. Natl Acad. Sci. USA 116, 26523\u201326533 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2661_CR41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1073\/pnas.1519214113","volume":"113","author":"G Veggiani","year":"2016","unstructured":"Veggiani, G. et al. Programmable polyproteams built using twin peptide superglues. Proc. Natl Acad. Sci. USA 113, 1202\u20131207 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2661_CR42","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl Acad. Sci. USA 109, E690\u2013E697 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2661_CR43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"2661_CR44","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.immuni.2016.11.010","volume":"45","author":"E Kuroda","year":"2016","unstructured":"Kuroda, E. et al. Inhaled fine particles induce alveolar macrophage death and interleukin-1\u03b1 release to promote inducible bronchus-associated lymphoid tissue formation. Immunity 45, 1299\u20131310 (2016).","journal-title":"Immunity"},{"key":"2661_CR45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","volume":"344","author":"S Meier","year":"2004","unstructured":"Meier, S., G\u00fcthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051\u20131069 (2004).","journal-title":"J. Mol. Biol."},{"key":"2661_CR46","doi-asserted-by":"crossref","first-page":"24650","DOI":"10.1021\/acsnano.3c10797","volume":"18","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Nanoplatform based intranasal vaccines: current progress and clinical challenges. ACS Nano 18, 24650\u201324681 (2024).","journal-title":"ACS Nano"},{"key":"2661_CR47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14760584.2021.1903878","volume":"21","author":"R Heida","year":"2022","unstructured":"Heida, R., Hinrichs, W. L. & Frijlink, H. W. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert Rev. Vaccines 21, 957\u2013974 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"2661_CR48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/17425247.4.6.651","volume":"4","author":"B Pulliam","year":"2007","unstructured":"Pulliam, B., Sung, J. C. & Edwards, D. A. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin. Drug Deliv. 4, 651\u2013663 (2007).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2661_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","volume":"624","author":"T Ye","year":"2023","unstructured":"Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630\u2013638 (2023).","journal-title":"Nature"},{"key":"2661_CR50","doi-asserted-by":"crossref","DOI":"10.1126\/science.adx6291","volume":"391","author":"A Romanov","year":"2026","unstructured":"Romanov, A. et al. DNA origami vaccines program antigen-focused germinal centers. Science 391, eadx6291 (2026).","journal-title":"Science"},{"key":"2661_CR51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 53, 548\u2013563 (2020).","journal-title":"Immunity"},{"key":"2661_CR52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines10020153","volume":"10","author":"O \u0110akovi\u0107 Rode","year":"2022","unstructured":"\u0110akovi\u0107 Rode, O. et al. Decline of anti-SARS-CoV-2 IgG antibody levels 6 months after complete BNT162b2 vaccination in healthcare workers to levels observed following the first vaccine dose. Vaccines 10, 153 (2022).","journal-title":"Vaccines"},{"key":"2661_CR53","doi-asserted-by":"crossref","first-page":"e175233","DOI":"10.1172\/JCI175233","volume":"135","author":"Y Lin","year":"2025","unstructured":"Lin, Y. et al. Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. J. Clin. Invest. 135, e175233 (2025).","journal-title":"J. Clin. Invest."},{"key":"2661_CR54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-025-08910-6","volume":"641","author":"H Kiyono","year":"2025","unstructured":"Kiyono, H. & Ernst, P. B. Nasal vaccines for respiratory infections. Nature 641, 321\u2013330 (2025).","journal-title":"Nature"},{"key":"2661_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41565-023-01553-6","volume":"19","author":"G Liu","year":"2024","unstructured":"Liu, G. et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat. Nanotechnol. 19, 387\u2013398 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"2661_CR56","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-023-37225-1","volume":"14","author":"X Ma","year":"2023","unstructured":"Ma, X. et al. Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field. Abstract. Nat. Commun. 14, 1606 (2023).","journal-title":"Abstract. Nat. Commun."},{"key":"2661_CR57","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","volume":"6","author":"Y Yue","year":"2022","unstructured":"Yue, Y. et al. Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria. Nat. Biomed. Eng. 6, 898\u2013909 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2661_CR58","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","volume":"12","author":"K Cheng","year":"2021","unstructured":"Cheng, K. et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nat. Commun. 12, 2041 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02661-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:02:57Z","timestamp":1787752977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41563-026-02661-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1038\/s41563-026-02661-z","relation":{},"ISSN":["1476-1122","1476-4660"],"issn-type":[{"value":"1476-1122","type":"print"},{"value":"1476-4660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Q.F., J.Z. and X.Z. are inventors on a filed provisional application of Chinese patent (Nano-assembly of antigens based on DNA origami and the application in vaccine) submitted by the National Center for Nanoscience and Technology and Beijing Intell Nanomedicine that covers the potential diagnostic and therapeutic uses of DNA\u2013antigen complexes. X.Z., G.N., X.G. and K.C. are inventors on a filed provisional application of Chinese patent (A subunit vaccine based on DNA origami and the application in vaccine) submitted by the National Center for Nanoscience that covers the potential therapeutic uses of ICO-RSV. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}